Success Metrics

Clinical Success Rate
71.8%

Based on 176 completed trials

Completion Rate
72%(176/245)
Active Trials
145(30%)
Results Posted
82%(144 trials)
Terminated
69(14%)

Phase Distribution

Ph not_applicable
5
1%
Ph phase_3
74
15%
Ph phase_4
2
0%
Ph phase_2
201
42%
Ph early_phase_1
4
1%
Ph phase_1
190
40%

Phase Distribution

194

Early Stage

201

Mid Stage

76

Late Stage

Phase Distribution476 total trials
Early Phase 1First-in-human
4(0.8%)
Phase 1Safety & dosage
190(39.9%)
Phase 2Efficacy & side effects
201(42.2%)
Phase 3Large-scale testing
74(15.5%)
Phase 4Post-market surveillance
2(0.4%)
N/ANon-phased studies
5(1.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.2%

176 of 270 finished

Non-Completion Rate

34.8%

94 ended early

Currently Active

145

trials recruiting

Total Trials

479

all time

Status Distribution
Active(162)
Completed(176)
Terminated(94)
Other(47)

Detailed Status

Completed176
Recruiting88
Terminated69
Active, not recruiting57
unknown44
Withdrawn25

Development Timeline

Analytics

Development Status

Total Trials
479
Active
145
Success Rate
71.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (0.8%)
Phase 1190 (39.9%)
Phase 2201 (42.2%)
Phase 374 (15.5%)
Phase 42 (0.4%)
N/A5 (1.1%)

Trials by Status

unknown449%
not_yet_recruiting174%
recruiting8818%
withdrawn255%
completed17637%
terminated6914%
active_not_recruiting5712%
suspended31%

Recent Activity

Clinical Trials (479)

Showing 20 of 479 trialsScroll for more
NCT06422143Phase 3

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Recruiting
NCT03606967Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
NCT06841354Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Recruiting
NCT03907475Phase 2

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Recruiting
NCT05630183Phase 2

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Completed
NCT05852691Phase 2

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Active Not Recruiting
NCT06096844Phase 3

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting
NCT06926868Phase 2

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Recruiting
NCT06692738Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting
NCT02481635Phase 1

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Active Not Recruiting
NCT07221474Phase 2

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Recruiting
NCT07226856Phase 2

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Recruiting
NCT07283705Phase 2

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Recruiting
NCT07060807Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Recruiting
NCT06312176Phase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Recruiting
NCT07063745Phase 2

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Recruiting
NCT05017012Phase 1

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Completed
NCT05285358Phase 1

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Suspended
NCT03816163Phase 2

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Active Not Recruiting
NCT07628062Phase 2

Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
479